home / stock / bcab / bcab short
Short Information | BioAtla Inc. (NASDAQ:BCAB)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 2,711,398 |
Total Actual Volume | 20,268,632 |
Short Trends | |
---|---|
Cover Days | 20 |
Short Days | 0 |
No Change Days | 0 |
Averages | |
---|---|
Average Short Volume | 135,570 |
Average Short Percentage | 16.53% |
Is there a BCAB Short Squeeze or Breakout about to happen?
See the BCAB Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
07-16-2024 | $1.78 | $2.05 | $2.09 | $1.75 | 1,197,317 | 175,405 | 14.65% |
07-15-2024 | $1.85 | $1.75 | $1.92 | $1.66 | 941,024 | 109,329 | 11.62% |
07-12-2024 | $1.63 | $1.8 | $1.82 | $1.58 | 887,252 | 136,481 | 15.38% |
07-11-2024 | $1.48 | $1.6 | $1.66 | $1.44 | 754,397 | 63,609 | 8.43% |
07-10-2024 | $1.27 | $1.42 | $1.4472 | $1.19 | 1,075,855 | 176,615 | 16.42% |
07-09-2024 | $1.31 | $1.17 | $1.31 | $1.14 | 1,715,645 | 390,438 | 22.76% |
07-08-2024 | $1.32 | $1.27 | $1.37 | $1.24 | 640,185 | 89,908 | 14.04% |
07-05-2024 | $1.43 | $1.32 | $1.43 | $1.32 | 643,393 | 150,257 | 23.35% |
07-03-2024 | $1.34 | $1.43 | $1.45 | $1.29 | 825,802 | 66,735 | 8.08% |
07-02-2024 | $1.36 | $1.32 | $1.41 | $1.26 | 923,492 | 148,471 | 16.08% |
07-01-2024 | $1.34 | $1.35 | $1.405 | $1.29 | 1,045,027 | 170,848 | 16.35% |
06-28-2024 | $1.44 | $1.37 | $1.52 | $1.37 | 5,763,602 | 261,423 | 4.54% |
06-27-2024 | $1.42 | $1.47 | $1.545 | $1.36 | 610,779 | 122,642 | 20.08% |
06-26-2024 | $1.53 | $1.41 | $1.65 | $1.4 | 755,092 | 150,377 | 19.92% |
06-25-2024 | $1.54 | $1.53 | $1.56 | $1.5 | 343,152 | 35,780 | 10.43% |
06-24-2024 | $1.48 | $1.56 | $1.59 | $1.45 | 397,504 | 68,798 | 17.31% |
06-21-2024 | $1.42 | $1.51 | $1.585 | $1.42 | 522,661 | 123,587 | 23.65% |
06-20-2024 | $1.55 | $1.415 | $1.62 | $1.41 | 586,979 | 129,431 | 22.05% |
06-18-2024 | $1.58 | $1.6 | $1.67 | $1.52 | 380,908 | 73,532 | 19.3% |
06-17-2024 | $1.58 | $1.56 | $1.62 | $1.535 | 258,566 | 67,732 | 26.2% |
News, Short Squeeze, Breakout and More Instantly...
SAN DIEGO, June 27, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced it will host a virtual R&D Day ar...
SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management w...
Multiple refractory PD1 failure patients experienced prolonged progression free survival (10 months ongoing); confirmed responses observed in patients receiving evalstotug High doses of evalstotug as either a monotherapy or in combination with PD1 are associated with manageable safety w...